BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The oncogenic potential of BCR/ABL-carrying EVs has also been confirmed in vivo in immunodeficient NOD/SCID mice, where administration of BCR/ABL EVs resulted in the formation of chronic myelogenous leukemia (CML)-like phenotype, with characteristics of CML such as feeble, febrile, thin, and with splenomegaly and neutrophilia but with reduced neutrophil phagocytic activity [40].